We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+3.49%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$14.5B
AUM Growth
+$941M
(+6.9%)
Cap. Flow
+$1.2B
Cap. Flow
% of AUM
8.27%
Top 10 Holdings %
Top 10 Hldgs %
50.76%
Holding
909
New
194
Increased
274
Reduced
256
Closed
181
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RMP
Rice Midstream Partners LP
RMP
|
+$126M |
| 2 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$90.9M |
| 3 |
Enterprise Products Partners
EPD
|
+$88.4M |
| 4 |
Plains All American Pipeline
PAA
|
+$78.1M |
| 5 |
WES
Western Gas Partners Lp
WES
|
+$63.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pitney Bowes
PBI
|
+$36.3M |
| 2 |
FTR
Frontier Communications Corp.
FTR
|
+$34.8M |
| 3 |
Brookfield
BN
|
+$32.6M |
| 4 |
Royal Gold
RGLD
|
+$15.5M |
| 5 |
Danaher
DHR
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 65.56% |
| 2 | Materials | 2.69% |
| 3 | Financials | 2.68% |
| 4 | Healthcare | 2.39% |
| 5 | Industrials | 2.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADAP
676
DELISTED
Adaptimmune Therapeutics
ADAP
| $336K | ﹤0.01% |
60,896
-7,128
| -10% | -$31.2K |
|
677
Neurogene
NGNE
$696M
| $336K | ﹤0.01% |
1,008
-117
| -10% | -$41.1K |
|
678
Progressive
PGR
$124B
| $336K | ﹤0.01% |
+8,586
| New | +$328K |
|
679
Expeditors International
EXPD
$22.9B
| $332K | ﹤0.01% |
5,874
+1,289
| +28% | +$70.7K |
|
|
ADMS
680
DELISTED
Adamas Pharmaceuticals
ADMS
| $331K | ﹤0.01% |
18,910
-2,215
| -10% | -$37.7K |
|
681
Alphabet (Google) Class A
GOOGL
$3.91T
| $327K | ﹤0.01% |
7,720
-19,920
| -72% | -$838K |
|
|
CNCE
682
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $327K | ﹤0.01% |
19,162
-2,244
| -10% | -$26.9K |
|
683
American Express
AXP
$223B
| $325K | ﹤0.01% |
+4,113
| New | +$322K |
|
|
MDP
684
DELISTED
Meredith Corporation
MDP
| $325K | ﹤0.01% |
+5,034
| New | +$310K |
|
|
PARA
685
DELISTED
Paramount Global Class B
PARA
| $318K | ﹤0.01% |
+4,587
| New | +$301K |
|
|
OTIC
686
DELISTED
Otonomy, Inc.
OTIC
| $318K | ﹤0.01% |
25,976
-3,038
| -10% | -$44.2K |
|
|
BGC
687
DELISTED
General Cable Corporation
BGC
| $318K | ﹤0.01% |
+17,707
| New | +$318K |
|
688
Sysco
SYY
$39.7B
| $316K | ﹤0.01% |
+6,080
| New | +$322K |
|
689
Akebia Therapeutics
AKBA
$327M
| $303K | ﹤0.01% |
32,970
-3,860
| -10% | -$37.7K |
|
|
CCXI
690
DELISTED
ChemoCentryx, Inc.
CCXI
| $299K | ﹤0.01% |
41,127
-4,815
| -10% | -$34.7K |
|
691
Old Republic International
ORI
$10.3B
| $298K | ﹤0.01% |
+14,558
| New | +$294K |
|
692
Target
TGT
$62.1B
| $297K | ﹤0.01% |
+5,377
| New | +$335K |
|
|
WRI
693
DELISTED
Weingarten Realty Investors
WRI
| $294K | ﹤0.01% |
9,761
-1,591
| -14% | -$55.6K |
|
|
LHO
694
DELISTED
LaSalle Hotel Properties
LHO
| $294K | ﹤0.01% |
+11,123
| New | +$330K |
|
|
OMED
695
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $294K | ﹤0.01% |
31,910
-3,735
| -10% | -$32.8K |
|
696
PTC Therapeutics
PTCT
$6.37B
| $291K | ﹤0.01% |
29,524
-3,455
| -10% | -$41.8K |
|
697
Jack in the Box
JACK
$278M
| $287K | ﹤0.01% |
+2,822
| New | +$292K |
|
698
Citigroup
C
$222B
| $278K | ﹤0.01% |
4,655
-7,694
| -62% | -$455K |
|
|
FITB
699
Fifth Third Bancorp
FITB
$52B
| $274K | ﹤0.01% |
10,790
-13,681
| -56% | -$365K |
|
700
Northern Trust
NTRS
$22.2B
| $265K | ﹤0.01% |
+3,063
| New | +$266K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q1 2017 Portfolio in Review
As of Q1 2017, ALPS Advisors held 909 positions worth $14.5B, up 6.9% from $13.6B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
ALPS Advisors deployed $1.2B of net new capital in Q1 2017, opening 194 new positions and adding to 274 existing holdings. Its largest new stake was Newmont: 609,201 shares worth $20.1M.
By sector, the portfolio is most concentrated in Energy at 66% of assets, down from 67% a quarter earlier, followed by Materials and Financials.
On the sell side, the largest reduction was Royal Gold, an estimated $15.5M trimmed.
- ALPS Advisors's largest Q1 2017 buy was Newmont: 609,201 shares worth $20.1M.
- ALPS Advisors added most to Rice Midstream Partners LP in Q1 2017, an estimated $126M increase.
- ALPS Advisors's biggest Q1 2017 reduction was Royal Gold, cutting an estimated $15.5M.
- ALPS Advisors fully exited Pitney Bowes in Q1 2017, selling an estimated $36.3M.
- ALPS Advisors's ten largest holdings make up 51% of its $14.5B portfolio in Q1 2017.
- ALPS Advisors opened 194 new positions and closed 181 in Q1 2017.
- ALPS Advisors's portfolio value rose 6.9% quarter-over-quarter to $14.5B.
Based on ALPS Advisors's 13F filing for Q1 2017, filed 12 May 2017.